Title for MeetingAbstracts
Alphabetical listing of titles
HIV vaccine efficacy trials: what we have learned about women's perception of risk behavior change and experiences of risk reduction counseling.
HIV vaccine efforts at Chiron: polynucleotide, protein subunit, and prime/boost approaches.
HIV vaccine literacy in the developing world: Experiences from Kenya.
HIV vaccine preparedness in Trinidad and Tobago.
HIV vaccine preparedness initiative among injecting drug users in Baltimore, Maryland.
HIV vaccine preparedness: Capacity-Building needs of community-based AIDS organizations.
HIV vaccine targeting the Tat protein requires full-length Tat protein.
HIV vaccine therapy: phase 1 safety and immunogenicity using gp160.
HIV vaccine trial design for measuring vaccine effects on infectiousness and the basic reproduction number.
HIV vaccine trial participation and recruitment in South Africa -- concerns of medical professionals in the western cape.
HIV Vaccine Trial Preparedness in a High Risk Clade B Heterosexual Cohort in Trinidad and Tobago.
HIV vaccine trials in developing countries - the UNAIDS perspective.
HIV VACCINE TRIALS IN DEVELOPING COUNTRIES: VULNERABILITY, EXPLOITATION AND THE NEEDFOR CAUTION.
HIV Vaccines - Update on Global Vaccine Efforts.
HIV vaccines and African Americans.
HIV vaccines trials and the proposed changes of the Declaration of Helsinki: the fallacy of urgency or ethics vs economics.
HIV vaccines.
HIV vaccines: resolved that more fundamental research on vaccine development is required prior to the implementation of phase III trials of certain HIV vaccines.
HIV vaccines: resolved that more fundamental research on vaccine development is required prior to the implementation of phase III trials of HIV vaccines.
HIV Vaccines: The Clinical Trials Experience.
HIV vaccines: what's going on?
HIV variability and host control in HIV pathogenesis.
HIV variability and its implications for pathogenesis.
HIV variants and rapid tests for HIV infection diagnosis.
HIV VCT services in Chennai, India: Expeditor or Hurdle.
HIV vertical transmission in Buenos Aires: follow-up.
HIV vertical transmission in Rio De Janeiro: rate and risk factors.
HIV vertical transmission with a maternal viral load between 1,000 e 10,000 copies in Rio de Janeiro, Brazil.
HIV Vif and the Evasion of Host Anti-viral Resistance.
HIV Vif: Deactivation of a Deadly Deaminase.